Nevro (NVRO) Gets a Buy Rating from BMO Capital


BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Nevro (NYSE: NVRO) yesterday and set a price target of $76. The company’s shares closed yesterday at $58.94.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.5% and a 71.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.

Currently, the analyst consensus on Nevro is a Moderate Buy with an average price target of $76.75, implying a 30.2% upside from current levels. In a report issued on July 25, Canaccord Genuity also maintained a Buy rating on the stock with a $80 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $94.34 and a one-year low of $35.41. Currently, Nevro has an average volume of 969.1K.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVRO in relation to earlier this year. Earlier this month, Doug Alleavitch, the VP, Quality of NVRO bought 1,000 shares for a total of $53,700.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nevro Corp. engages in the provision of medical devices. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts